Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2024-01-01 DOI:10.2174/0113894501286195231220094646

Junhui Wu, Jing Wei, Haoliang Chen, Yalong Dang, Fang Lei

引用次数: 0

Abstract

Glaucoma is the most common cause of irreversible blindness worldwide. It is characterized by progressive optic nerve degeneration and loss of visual field. Pathological increased intraocular pressure is its main modifiable risk factor. Rho kinase inhibitors are developed as a new class of glaucoma medication that increases outflow facility from the conventional aqueous humor outflow pathway. Additionally, they also have neuroprotective and anti-scarring effects that can might increase the success rate of glaucoma filtration surgery. This review aims to summarize the current concept of Rho kinase inhibitors in the treatment of glaucoma from beach to bedside.

查看原文本刊更多论文

治疗青光眼的 Rho 激酶 (ROCK) 抑制剂。

青光眼是全球最常见的不可逆致盲原因。其特点是视神经逐渐退化和视野缺失。病理性眼压升高是其主要的可改变风险因素。Rho 激酶抑制剂是作为一种新型青光眼药物开发的，可增加传统房水流出途径的流出量。此外，它们还具有神经前瞻性和抗瘢痕作用，可提高青光眼滤过手术的成功率。本综述旨在总结目前 Rho 激酶抑制剂在青光眼治疗中从海滩到床边的治疗理念。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.